Ionis Shares Jump As It Deepens Biogen Ties In Neurology Drugs [Investor's Business Daily]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Investors Business Daily
Related news 4/10/2018 Audentes, Spark and uniQure popped Tuesday after Novartis' $8.7 billion plan to buy AveXis put a spotlight on other gene... AbbVie Deal Allows Biogen To Launch Humira Copy In Europe Why Gilead Looks Strong In First Quarter, But These Biotechs Are Shakier How Pfizer Sneaked Into Rare-Disease Market And Hit Alnylam, Ionis Pfizer Takes On Alnylam, Ionis With Rare Disease Treatment Biogen, AbbVie Pull Multiple Sclerosis Drug On Inflammation Reports What Does A Double-Bottom Base Look Like? This Top Biotech Stock Formed A Great One How Celgene 'Gambled' On Ozanimod — And Why It Didn't Pay Off Biogen's Multiple Sclerosis Drug Franchise Takes Another Hit Ionis Pharmaceuticals ( IONS ) rocketed in early trading Friday after announcing a $1 billion deal with Biogen ( BIIB ) to develop treatments for neurological diseases like dementia, following up the success they've had with Spinraza. Shares of Ionis popped 7.1%, near 49.10, i
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis to hold first quarter 2024 financial results webcastPR Newswire
- Bepirovirsen for Chronic Hepatitis B Drug Pipeline Report 2024: 7MM Market Size, Forecast, and Emerging Insights 2019-2032 [Yahoo! Finance]Yahoo! Finance
- n-Lorem Foundation Collaborates with Across Healthcare to Develop a Custom Submission Platform for Physicians of Nano-rare Patients [Yahoo! Finance]Yahoo! Finance
- n-Lorem Foundation Announces the Second Annual Nano-rare Patient Colloquium Will be Held on Oct. 30 & 31, 2024 [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating.MarketBeat
IONS
Earnings
- 2/21/24 - Beat
IONS
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- 4/16/24 - Form 144
- IONS's page on the SEC website